Wyeth Licenses Osteoporosis Drug Targets From Galapagos

Wyeth agrees to second milestone stemming from 2003 agreement, selecting three novel Galapagos targets for osteoporosis.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet